How to Read Your FibroScan Report: CAP and kPa Explained
A FibroScan gives you two numbers. CAP, in dB/m, is how much fat is in your liver. kPa is how stiff the liver is, which tells you how much scarring has formed. The scarring number is the one that matters most: a kPa under 8 effectively rules out advanced scarring in fatty liver, while a CAP of 248 dB/m and up means fat is present. Read the stiffness first, then the fat.
Reviewed by Dr. Rejeesh Menon, MBBS, MD, FACP, Internal Medicine (TCMC Reg. 40073). Last reviewed 24 October 2026.
The fat number
CAP measures liver fat. Fat weakens the ultrasound beam, so the more the signal is dimmed, the higher the CAP and the more fat is present. It confirms and sizes the fat, but on its own it does not decide treatment.
The scarring number
kPa measures stiffness. The probe sends a shear wave into the liver and times it; a scarred, stiffer liver carries the wave faster. This is the number that predicts long-term risk, so it is the one to read first.
Your CAP score (dB/m): how much fat
CAP sorts liver fat into four bands. The cut-offs below are the most-cited set, from a 2,735-patient analysis (Karlas 2017), but treat them as estimates: published CAP thresholds move by roughly 10 to 20 dB/m between studies and machines, and the fat percentages are approximate.
| Grade | Meaning | CAP (dB/m) | Approx. liver fat |
|---|---|---|---|
| S0 | None / minimal | Under 248 dB/m | Under 5% of liver cells |
| S1 | Mild | 248 to 267 dB/m | Roughly 5 to 33% |
| S2 | Moderate | 268 to 279 dB/m | Roughly 34 to 66% |
| S3 | Severe | 280 dB/m and above | Roughly 67% or more |
Your kPa score: stiffness and the F0 to F4 stages
Stiffness is the number with the strongest evidence and the one that drives whether you are referred. These are the fatty liver (MASLD) values from EASL 2024 and AASLD 2023, which are different from the numbers used for viral hepatitis.
| Stage | Meaning | Stiffness (kPa) | What it means for you |
|---|---|---|---|
| F0 to F1 | None to mild | Under 8 kPa | Advanced scarring effectively ruled out. Keep working on the metabolic drivers. |
| F2 | Significant | 8 to 9.9 kPa | A grey zone. Read it alongside a FIB-4 score, repeat the scan, or get a specialist opinion. |
| F3 | Advanced | 10 to 12 kPa | Likely advanced scarring. This is a hepatology assessment, not a wait-and-see. |
| F4 | Cirrhosis | 12 kPa and above | Suggests advanced chronic liver disease. Above 15 kPa it is highly suggestive. Needs a liver specialist. |
FibroScan cost in India and Kerala
A FibroScan scan in India generally costs about 2,000 to 5,000 rupees. Standalone diagnostic centres sit at the lower end; some super-speciality hospitals quote up to around 7,000 rupees. This is a one-time diagnostic test fee, not a recurring cost. Prices in Kerala vary by centre, so confirm the exact charge with the facility before you book.
One thing to check on a high quote: a blood-panel fibrosis test (sometimes sold under a similar name) is a different thing from the scan and is often priced higher. If you are unsure which you are being quoted for, ask whether it is the probe-on-the-skin scan that gives a CAP and a kPa number.
How to prepare, and when the number can be wrong
Fast for at least 3 hours before the scan. A recent meal raises blood flow through the liver and can push the stiffness reading up falsely. The test itself is painless, takes 5 to 10 minutes, uses no needles and no sedation.
A FibroScan can read falsely stiff during an acute liver flare (a big jump in SGPT and SGOT), with heart-failure congestion of the liver, or with a blocked bile duct. People with a larger body size need the XL probe rather than the standard M probe, because a thicker chest wall defeats the M probe; the probe used is printed on the report and changes which thresholds apply. A reliable result needs at least 10 valid readings and an IQR to median ratio under 30%. If your report does not meet that, the number should be repeated, not trusted.
How to read the numbers on your actual report
Your report prints more than the two headline numbers. Here is what each field means.
| On your report | What it means |
|---|---|
| Median stiffness (kPa) | The main scarring result, and the number the F0 to F4 stages use. |
| IQR / median | The reliability check. It should be under 30%. Higher means the readings were scattered and the result is less trustworthy. |
| Valid measurements | Should be at least 10. Fewer than that, and the scan should be repeated. |
| CAP (dB/m) | The fat number, sometimes printed with its own IQR. |
| Probe (M or XL) | XL is used for a larger body size. The stiffness thresholds are the same; the machine accounts for the probe. |
A worked read. A report saying median 5.2 kPa, IQR/median 11%, 10 valid measurements, CAP 290 dB/m, M probe is a reliable scan: plenty of fat (severe steatosis by CAP) but stiffness well under 8, so no meaningful scarring yet. The sensible response is to lose the fat before it ever becomes scar.
Who should not have a FibroScan, or when it cannot give a reading
- Pregnancy. The scan is avoided in pregnancy because its safety there has not been established.
- An implanted cardiac device, such as a pacemaker or a defibrillator. It is avoided because the effect of the probe's pulse on the device has not been fully assessed, so tell the centre before you book.
- Ascites, fluid in the abdomen. Not a safety problem, but the fluid stops the wave travelling, so the scan usually cannot give a valid stiffness number and a blood-based test is used instead.
FibroScan, ultrasound, FIB-4 and SGPT: which tells you what
These tests answer different questions, and a good assessment uses them together rather than relying on any one.
| Test | What it measures | Scarring? | In one line |
|---|---|---|---|
| FibroScan (this page) | Fat (CAP) and scarring (kPa) | Yes, directly | The only one here that puts a number on scarring without a biopsy. |
| FIB-4 blood score | Fibrosis risk from age, AST, ALT, platelets | Estimates it | Free, done from blood you already have, and decides who needs a FibroScan. |
| Ultrasound grade (1 to 3) | Fat only, by brightness | No | Operator dependent and misses fat below about 20%. Cannot stage scarring. |
| SGPT / ALT (LFT) | Liver inflammation enzymes | No | Often normal even when real scarring is present, so a normal SGPT does not clear you. |
Run your FIB-4 fibrosis calculator first, see what an ultrasound grade does and does not tell you, and check why a normal SGPT / ALT result does not clear you.
When you actually need a FibroScan
EASL 2024 uses a simple two-step pathway: a FIB-4 score first, then a FibroScan for the people it flags. You are in the group that benefits from the scan if any of these fit: a FIB-4 in the grey zone of 1.3 to 2.67; type 2 diabetes with fatty liver; an SGPT that stays high without another cause; Indian-threshold obesity (BMI 25 and over) with metabolic syndrome; or fatty liver seen on an ultrasound alongside any metabolic risk factor. A FibroScan is what moves you from "you have fatty liver" to "we know whether it has started to scar."
When your result means see a specialist soon, not later
A kPa above 12 suggests advanced scarring and needs a liver specialist. Above 15 it is highly suggestive of advanced chronic liver disease, and 20 to 25 and up, especially with a low platelet count, points to raised pressure in the liver circulation and needs prompt assessment.
These are a medical emergency whatever your kPa number is: yellowing of the eyes or skin, a swelling abdomen with fluid, new confusion or drowsiness, or vomiting blood or passing black tarry stools. Go to a hospital now, do not wait for a clinic appointment. In India you can call 112.
Can your FibroScan numbers improve?
Yes, and this is the hopeful part. The fat number (CAP) falls first and fastest: as weight comes down and refined carbohydrate drops, liver fat falls, often within months. The stiffness number (kPa) moves more slowly, but early scarring is not fixed in stone. With the metabolic drivers treated and a sustained 7 to 10 percent weight loss, inflammation settles and early fibrosis can regress, so a repeat scan a year on often reads lower. Established cirrhosis, a high and confirmed kPa, is managed rather than reversed, which is exactly why catching a rising number early matters. A FibroScan is not only a verdict, it is a baseline you can move.
At DermaVue this is handled as physician-supervised metabolic health: we read your scan, treat the drivers behind it, and repeat the measurement to track real change. The full fatty liver guide sets out the treatment evidence.
Bring your FibroScan report to a physician
If you have a CAP and kPa number and are not sure what they mean for you, a physician can read them alongside your blood work, weight and blood sugar and tell you honestly what the next step is. DermaVue does not run the scanner itself; the scan is done at a diagnostic centre or hospital, and if you have not had it yet we help you arrange it at a centre near you. The review and the plan are a video consultation across South India, with home blood collection and medicine home delivery where needed.
Get your FibroScan report reviewed by a physicianYour questions about FibroScan, CAP and kPa
Next steps
FIB-4 fibrosis calculator
The free blood-score that decides whether you need a FibroScan at all.
Ultrasound grade 1, 2, 3 explained
What your ultrasound fatty-liver grade means, and why it is only about fat.
SGPT / ALT liver function test
Why a normal enzyme report does not clear you of scarring.
Fatty Liver (MASLD): the full guide
Diagnosis, staging, and the treatment evidence in one place.
References
- EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492-542. View on DOI
- Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. View on PubMed
- de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII: renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959-974. View on PubMed
- Berzigotti A, Tsochatzis E, Boursier J, et al. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2021;75(3):659-689. View on PubMed
- Karlas T, Petroff D, Sasso M, et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) for the assessment of hepatic steatosis. J Hepatol. 2017;66(5):1022-1030. View on PubMed
- Sandrin L, Fourquet B, Hasquenoph JM, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29(12):1705-1713. View on PubMed